Pharmaceuticals, Biotechnology and Life Sciences
Axsome Therapeutics’ AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the prespecified primary endpoint and significantly improved symptoms of depression in the ASCEND Phase 2 trial in major depressive disorder (MDD), the company said Monday.
Adverum Biotechnologies, a California-based ophthalmology and rare diseases focused biotech company, expects to provide an update on enrollment from the OPTIC phase 1 clinical trial in the first half of 2019, and interim data on the three cohorts from the OPTIC phase 1 clinical trial by the first quarter of 2020, it said in an outlook for 2019.
New York-based cancer therapeutics company, Stelexis Therapeutics has closed a $43 million Series A financing to expand its proprietary platform to discover and selectively target pre-cancerous stem cells.
AstraZeneca has reached a clinical development milestone with immuno-oncology candidate AZD4635, thus triggering a $15 million payment to its partner, Sosei Group.
4D pharma and The University of Texas MD Anderson Cancer Center will together work on testing 4D’s Live Biotherapeutic oncology pipeline across a range of cancer settings, the company said on Monday in a press release
Orexo AB’s nasal spray formulations for opioid overdose reversal has been compared to Narcan in a study, in which it showed similar or better results, the company said in a press release on Monday.
Regeneron Pharmaceuticals and Sanofi restructure immuno-oncology agreement from 2015, where Regeneron retains full rights to all its other investigational immunooncology programsto, while Sanofi is able to independently chase own immuno-oncology programs.
Neumentum said Monday that findings from its phase I study of NTM-001 (pre-mixed bag ketorolac for continuous infusion), confirmed the investigational non-opioid pain treatment performs as it predicted in healthy adult volunteers.
DiscGenics’s IDCT cell therapy has passed the initial planned safety review of its Phase I/II trial evaluating the allogeneic, injectable disc cell therapy in patients with mild to moderate degenerative disc disease (DDD).
Schreiner MediPharm’s trade fair presentation at Pharmapack 2019 in Paris will be fully focused on smart packaging solutions. On February 6 and 7, in Hall 7.2, Booth B32, the specialist for innovative labels and marking solutions with value-added benefits will showcase its latest product development in the field of digital therapy monitoring: The new “Smart Vial Kit” enables electronic tracking and monitoring of medication dispensing and intake.